News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
39,990 Results
Type
Article (1821)
Company Profile (6)
Press Release (38163)
Section
Business (17211)
Career Advice (19)
Deals (2798)
Drug Development (5147)
FDA (654)
Job Trends (806)
News (24681)
Policy (1308)
Tag
Academia (77)
Accelerated approval (1)
Allergies (3)
Alliances (1546)
ALS (5)
Alzheimer's disease (40)
Antibody-drug conjugate (ADC) (4)
Approvals (659)
Artificial intelligence (9)
Autoimmune disease (1)
Bankruptcy (17)
Best Places to Work (776)
Biosimilars (1)
Biotechnology (5)
Bladder cancer (8)
Brain cancer (1)
Breast cancer (28)
Cancer (188)
Cardiovascular disease (11)
Career advice (16)
CAR-T (9)
Cell therapy (27)
Clinical research (4448)
Collaboration (49)
Compensation (46)
Complete response letters (1)
COVID-19 (78)
C-suite (10)
Cystic fibrosis (5)
Data (241)
Depression (5)
Diabetes (19)
Diagnostics (317)
Digital health (1)
Drug discovery (7)
Drug pricing (1)
Duchenne muscular dystrophy (22)
Earnings (14968)
Editorial (2)
Events (5113)
Executive appointments (18)
FDA (797)
Frontotemporal dementia (1)
Funding (28)
Gene editing (5)
Generative AI (2)
Gene therapy (22)
GLP-1 (32)
Government (128)
Guidances (63)
Healthcare (1066)
IgA nephropathy (3)
Immunology and inflammation (8)
Indications (3)
Infectious disease (81)
Inflammatory bowel disease (7)
Influenza (1)
Intellectual property (1)
Interviews (2)
IPO (2238)
Job creations (70)
Job search strategy (13)
Layoffs (20)
Leadership (1)
Legal (229)
Liver cancer (3)
Lung cancer (17)
Lymphoma (29)
Machine learning (2)
Manufacturing (3)
MASH (5)
Medical device (922)
Medtech (922)
Mergers & acquisitions (620)
Metabolic disorders (46)
Multiple sclerosis (6)
NASH (2)
Neurodegenerative disease (4)
Neuropsychiatric disorders (1)
Neuroscience (79)
NextGen: Class of 2025 (216)
Non-profit (69)
Obesity (18)
Opinion (12)
Ovarian cancer (6)
Pain (8)
Pancreatic cancer (5)
Parkinson's disease (7)
Partnered (1)
Patents (14)
Patient recruitment (5)
Peanut (3)
People (1256)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase I (1272)
Phase II (1966)
Phase III (1640)
Pipeline (321)
Policy (4)
Postmarket research (171)
Preclinical (398)
Prostate cancer (5)
Radiopharmaceuticals (9)
Rare diseases (25)
Real estate (160)
Regulatory (1080)
Reports (3)
Research institute (57)
Resumes & cover letters (4)
RNA editing (1)
RSV (2)
Schizophrenia (11)
Series A (2)
Series B (2)
Service/supplier (1)
Sickle cell disease (1)
Spinal muscular atrophy (1)
Startups (129)
Stomach cancer (3)
Supply chain (2)
Tariffs (1)
Vaccines (32)
Venture capitalists (1)
Weight loss (12)
Date
Today (38)
Last 7 days (183)
Last 30 days (442)
Last 365 days (2900)
2025 (1210)
2024 (2964)
2023 (3386)
2022 (3623)
2021 (3851)
2020 (3178)
2019 (2152)
2018 (1564)
2017 (1440)
2016 (1038)
2015 (1526)
2014 (994)
2013 (525)
2012 (613)
2011 (867)
2010 (732)
Location
Africa (17)
Alabama (4)
Arizona (17)
Asia (2705)
Australia (218)
California (557)
Canada (130)
China (35)
Colorado (22)
Connecticut (42)
Delaware (23)
Europe (4512)
Florida (70)
Georgia (14)
Illinois (38)
India (2)
Indiana (29)
Iowa (2)
Japan (13)
Kansas (4)
Kentucky (2)
Louisiana (3)
Maine (6)
Maryland (53)
Massachusetts (363)
Michigan (13)
Minnesota (44)
Missouri (5)
Montana (2)
Nevada (4)
New Hampshire (8)
New Jersey (309)
New York (147)
North Carolina (79)
Northern California (274)
Ohio (16)
Pennsylvania (135)
Puerto Rico (2)
South America (32)
South Carolina (1)
Southern California (207)
Tennessee (1)
Texas (86)
United States (2224)
Utah (28)
Virginia (24)
Washington D.C. (3)
Washington State (114)
Wisconsin (2)
39,990 Results for "102".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
March 26, 2025
·
8 min read
Press Releases
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
May 7, 2025
·
6 min read
Press Releases
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
April 25, 2025
·
4 min read
Press Releases
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
April 28, 2025
·
7 min read
Press Releases
Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025
April 25, 2025
·
5 min read
Press Releases
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
April 28, 2025
·
8 min read
Press Releases
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
April 7, 2025
·
14 min read
Press Releases
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
April 4, 2025
·
4 min read
Press Releases
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
March 25, 2025
·
13 min read
Press Releases
LB Pharmaceuticals Presents New Data from Phase 2 Clinical Trial of LB-102 at the 2025 Annual Congress of the Schizophrenia International Research Society
April 1, 2025
·
5 min read
1 of 3,999
Next
